title: Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology.
abstract: Endocrine glands are well vascularised and the structure of their vessels facilitates the exchange of various substances, including hormones. These glands are a frequent experimental model in research on VEGF and angiogenesis. VEGF participates in the pathogenesis of diabetes. Diabetic nephropathy is in essence a microvascular disease that develops as a result of a confluence of haemodynamic and metabolic perturbations. Diabetic retinopathy is the commonest microvascular complication of diabetes mellitus and is the leading cause of blindness. In diabetic retinopathy, ischaemic states, and hence tissue hypoxia and angiogenesis, take place. The participation of angiogenesis and VEGF in the pathogenesis of neoplastic disease has been described in many papers. VEGF protein and mRNA have been found in cancers of the thyroid, bronchus, lungs, oesophagus, stomach, colon, liver, breast, ovary, uterus, kidney, and urinary bladder, and in malignant tumours of the brain and bone. There have been many reports of the connections between the degree of VEGF expression and tumour aggression and prognosis in patients. Richly vascularised are GEP NET. In neuroendocrine tumours, strong expression of VEGF, Flt-1 and KDR in relation to the unchanged surrounding tissues has been demonstrated. Depending on the disease entity or the degree of its severity, attempts to apply angiogenic and antiangiogenic therapy have being made. Antiangiogenic therapy (usually regarded as a form of cancer therapy) is based on: 1. inhibitory effects of proangiogenic ligands and their receptors; 2. stimulation or delivery of angiogenesis inhibitors; and 3. direct destruction of neoplastic tumour vasculature.
authors: Department of Pathophysiology and Endocrinology, Medical University of Silesia, Zabrze, Katowice, Poland. patofizjozab@sum.edu.pl
authors: Dariusz
authors: D
authors: Kajdaniuk
authors: Bogdan
authors: B
authors: Marek
authors: Wanda
authors: W
authors: Foltyn
authors: Beata
authors: B
authors: Kos-Kudła
mesh_terms: D020533:Angiogenesis Inhibitors / Q000378:metabolism* / Q000502:physiology; D003928:Diabetic Nephropathies / Q000503:physiopathology*; D004701:Endocrine Gland Neoplasms / Q000503:physiopathology*; D006801:Humans; D008113:Liver Neoplasms / Q000503:physiopathology*; D009389:Neovascularization, Pathologic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism* / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor